Verified July 2026 · Cited to primary sources

MGF (Mechano Growth Factor): Evidence Grade D. Animal studies only, unproven in humans.

Grade DResearch-onlySafety: amber

The honest verdict

Skip it. The idea (a local muscle-repair growth factor you can inject) is attractive, but the honest read of the literature is preclinical at best and negative in the one rigorous cell study. There is no human evidence it builds muscle, it is banned in sport, and injecting an unverified growth factor is not a low-risk bet.

MGF (Mechano Growth Factor) at a glance

Class
IGF-1 splice variant / growth factor peptide
Mechanism
MGF is the C-terminal E-domain of the IGF-1Ec splice variant, produced locally in skeletal muscle in response to mechanical overload or damage. The proposed mechanism is autocrine/paracrine activation of muscle satellite cells (the resident stem cells that repair and enlarge fibers), acting through a receptor distinct from the classic IGF-1 receptor. In practice the receptor and downstream signaling remain poorly characterized, and whether the synthetic peptide reproduces the biology of the natural splice event is unresolved.
Also known as
mechano growth factor, IGF-1Ec, IGF-1 Ec, MGF-E peptide
Research applications
  • Satellite cell activation studies
  • Muscle regeneration models
  • Local IGF-1 axis and sarcopenia research
Forms
Lyophilized powder for reconstitution (research chemical)
Legal status
Research-only
WADA (anti-doping)
Prohibited at all times (WADA S2, peptide hormones / growth factors class)
Evidence grade
Grade DAnimal studies only, unproven in humans

How we grade evidence

Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.

What is MGF (Mechano Growth Factor)?

A short splice variant of IGF-1 that muscle makes locally after mechanical stress. The theory is great, the human data barely exists, and the one well-run cell study said it did nothing.

MGF is the C-terminal E-domain of the IGF-1Ec splice variant, produced locally in skeletal muscle in response to mechanical overload or damage. The proposed mechanism is autocrine/paracrine activation of muscle satellite cells (the resident stem cells that repair and enlarge fibers), acting through a receptor distinct from the classic IGF-1 receptor. In practice the receptor and downstream signaling remain poorly characterized, and whether the synthetic peptide reproduces the biology of the natural splice event is unresolved.

How strong is the evidence for MGF (Mechano Growth Factor)?

Evidence is preclinical only. The optimistic case rests on cell-culture and animal work suggesting the MGF-E peptide can activate satellite cells. But a well-controlled 2014 in-vitro study explicitly designed to test it found the peptide had no effect on myoblast or muscle-stem-cell proliferation at concentrations up to 500 ng/ml, and a 2012 review concluded its efficacy in humans is unproven. There are no human trials showing MGF injections build muscle. Grade D reflects animal/in-vitro-only evidence with a notable negative result.

Primary sources (2)

  1. Fornaro M, et al. MGF peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab, 2014 (PMID 24253050).
  2. Zablocka B, et al. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol, 2012.

What is MGF (Mechano Growth Factor) used for?

MGF (Mechano Growth Factor) is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.

What does MGF (Mechano Growth Factor) cost, and how do you access it legally?

Typical cost

$25 to $60 per 2 mg vial (grey-market research supply)

Priced like other research peptides, but you are paying for a compound whose flagship controlled study showed no effect. Note that MGF and PEG-MGF are frequently mislabeled or underdosed by research vendors.

No legal supervised access route right now.

MGF (Mechano Growth Factor) has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole, so we don't link them. If you pursue MGF (Mechano Growth Factor), do it with a licensed clinician, and re-check its legal status first.

Is MGF (Mechano Growth Factor)safe? Side effects & risks

Limited human safety data, no major documented harms

Injectable research chemical with no approved human indication and no controlled human safety data. As an IGF-1 family growth factor, any real biological activity carries theoretical concerns around unregulated cell proliferation. Purity of grey-market lyophilized product is unverified. Prohibited in all sport by WADA.

Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.

FAQ

MGF (Mechano Growth Factor) FAQ

Does MGF actually build muscle in people?

There is no human trial showing that injected MGF builds muscle. The muscle-repair story comes from cell and animal work, and even that is contested: a 2014 controlled in-vitro study found the peptide did nothing to muscle cells.

Is MGF the same as IGF-1?

No. MGF is a splice variant of the IGF-1 gene (IGF-1Ec) and specifically its C-terminal E-domain peptide. It is proposed to act through a different receptor than mature IGF-1, though that receptor is not well defined.

Is MGF legal?

It is sold only as a research chemical, not as an approved or compoundable drug, and it is prohibited at all times under the WADA anti-doping code.

From our portfolio

Tracking MGF (Mechano Growth Factor)?

Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.

Get Titrate for iOS →

Keep reading

The monthly peptide evidence brief.

What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.

No spam. We never sell your email. Editorial policy.